ICAM1 and susceptibility to pneumonia measurement: They reported a lower incidence of pneumonia (OR 0.39, 95 per cent c.i. 0.16 to 0.96), and lower levels of ICAM-1 and soluble receptor for advanced glycation end-products (both markers of endothelial damage) in the salmeterol group, but no difference in the incidence of acute lung injury (ALI) (OR 1.25, 0.71 to 2.22).